{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:16:02Z","timestamp":1791645362395,"version":"4.3.4"},"reference-count":18,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Introduction<\/jats:bold>: Human immunodeficiency virus\u20101 (HIV\u20101) continues to have a high global burden, with approximately 39.9 million people currently living with the virus. Despite the clinical success of antiretroviral therapy (ART), adherence remains a significant challenge, often due to emotional distress and HIV\u2010related stigma. Long\u2010acting injectables (LAIs) such as the combination of cabotegravir (CAB) and rilpivirine (RPV) have emerged as promising alternatives, reducing the burden of daily pill regimens.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold>: This systematic review explores the role of CAB\u2009+\u2009RPV\u2010LA injectables in antiretroviral therapy (ART), with a focus on patient\u2010reported outcomes from five key clinical trials.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold>: Findings reveal that <jats:styled-content style=\"fixed-case\">CAB<\/jats:styled-content>\u2009+\u2009<jats:styled-content style=\"fixed-case\">RPV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">LA<\/jats:styled-content> maintains high levels of viral suppression comparable to daily <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content> while improving patient satisfaction and quality of life. Meta\u2010analysis of <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> Treatment Satisfaction Questionnaire (<jats:styled-content style=\"fixed-case\">HIVTSQc<\/jats:styled-content>) scores across multiple trials demonstrated consistent positive outcomes, with a mean score of 28.83 out of a possible range from \u221233 to +33, indicating a substantial improvement in patient satisfaction compared to baseline. Qualitative data highlight the psychological and logistical benefits of <jats:styled-content style=\"fixed-case\">LAIs<\/jats:styled-content>, including reduced stigma and enhanced treatment convenience.<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold>: This review underscores the potential of CAB\u2009+\u2009RPV\u2010LA in improving patient adherence and satisfaction while offering insights for future studies on longer\u2010term outcomes of LAI use.<\/jats:p>","DOI":"10.1111\/hiv.70058","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T23:53:46Z","timestamp":1751500426000},"page":"1343-1355","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Patient\u2010reported outcomes in clinical trials assessing the effectiveness of cabotegravir\u2009+\u2009rilpivirine long\u2010acting injections as antiretroviral therapy: A systematic review"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2417-1731","authenticated-orcid":false,"given":"Dhruv","family":"Vinay","sequence":"first","affiliation":[{"name":"Department of Medicine Queen's University  Kingston Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iresh","family":"Jayaweera","sequence":"additional","affiliation":[{"name":"Imperial College NHS Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Bowman","sequence":"additional","affiliation":[{"name":"Department of Medicine Queen's University  Kingston Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6568-7187","authenticated-orcid":false,"given":"Don Thiwanka D","family":"Wijeratne","sequence":"additional","affiliation":[{"name":"Department of Medicine Queen's University  Kingston Ontario Canada"},{"name":"Department of Public Health Queen's University  Kingston Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"World Health Organization.HIV \u2013 reported number of people receiving antiretroviral therapy.2024. Accessed September 30 2024.https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator\u2010details\/GHO\/reported\u2010number\u2010of\u2010people\u2010receiving\u2010antiretroviral\u2010therapy"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2014.14016"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461\u2010011\u20109942\u2010x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(17)31917\u20107"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524\u20104733.2006.00121.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2020.113092"},{"key":"e_1_2_6_9_1","volume-title":"Clinical Review Report: Cabotegravir Tablets, Cabotegravir Extended\u2010Release Injectable Suspension, and Rilpivirine Extended\u2010Release Injectable Suspension (Vocabria, Cabenuva): (ViiV Healthcare ULC): Indication: HIV\u20101 Infection","author":"CADTH Common Drug Reviews","year":"2020"},{"key":"e_1_2_6_10_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JPT","year":"2024"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190487"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(20)32666\u20100"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271\u2010021\u201000524\u20100"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0000000000002466"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909512"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13647"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000003085"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-024-04610-w"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2020.0120"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T10:45:31Z","timestamp":1756723531000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/hiv.70058"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70058","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"2025-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}